Skip to main content
Premium Trial:

Request an Annual Quote

BioreclamationIVT Acquires CRO TransCell Science

NEW YORK (GenomeWeb) – Biological specimen provider BioreclamationIVT announced today that it has acquired TransCell Science, a privately held contract research organization specializing in primary cell-based phenotypic screening assays.

"BioreclamationIVT and TransCell Science will form a complete solution spanning biospecimen acquisition to use of those samples within highly relevant in vitro assays," BioreclamationIVT CEO Jeff Gatz said in a statement.

Following the acquisition, TransCell Founder and CEO Chris Hansis will join BioreclamationIVT as CSO. Additional terms of the deal were not disclosed.